Profile data is unavailable for this security.
About the company
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
- Revenue in USD (TTM)425.17m
- Net income in USD-92.21m
- Incorporated2006
- Employees1.22k
- LocationNevro Corp1800 Bridge ParkwayREDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 251-0005
- Fax+1 (302) 655-5049
- Websitehttps://www.nevro.com
More ▼
Mergers & acquisitions
| Acquired company | NVRO:NYQ since announced | Transaction value |
|---|---|---|
| VYRSA Technologies Inc | -26.55% | 75.00m |
Data delayed at least 15 minutes, as of Apr 19 2024 17:36 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CVRx Inc | 39.30m | -41.20m | 319.36m | 200.00 | -- | 4.20 | -- | 8.13 | -1.99 | -1.99 | 1.89 | 3.64 | 0.3272 | 0.6974 | 6.02 | 196,475.00 | -34.31 | -- | -36.75 | -- | 84.08 | -- | -104.85 | -- | 12.86 | -23.96 | 0.2779 | -- | 74.89 | -- | 0.5528 | -- | -- | -- |
| Tactile Systems Technology Inc | 274.42m | 28.52m | 335.96m | 992.00 | 11.91 | 1.72 | 9.58 | 1.22 | 1.19 | 1.19 | 11.90 | 8.20 | 1.02 | 6.02 | 5.60 | 276,636.10 | 10.63 | 0.9015 | 13.23 | 1.09 | 49.95 | 49.10 | 10.39 | 0.8309 | 2.99 | -- | 0.1308 | 0.00 | 11.20 | 13.81 | 259.60 | 33.91 | -23.62 | -- |
| Bioventus Inc | 502.76m | -122.57m | 360.20m | 970.00 | -- | 2.02 | -- | 0.7165 | -1.97 | -2.93 | 8.06 | 2.25 | 0.4552 | 2.14 | 4.10 | 448,889.30 | -14.34 | -- | -18.91 | -- | 62.87 | 70.26 | -31.51 | -9.18 | 0.9443 | 0.3731 | 0.6354 | -- | 18.85 | 11.89 | -919.12 | -- | -- | -- |
| Zynex Inc | 184.32m | 9.73m | 365.59m | 1.10k | 42.77 | 8.30 | 26.20 | 1.98 | 0.2677 | 0.2677 | 5.10 | 1.38 | 1.45 | 2.86 | 5.96 | 167,565.50 | 7.68 | 14.58 | 9.11 | 17.52 | 79.38 | 79.62 | 5.28 | 10.44 | 4.03 | 9.85 | 0.5581 | -- | 16.54 | 42.01 | -42.91 | 0.3741 | 2.19 | -- |
| Surmodics Inc | 138.20m | 5.52m | 375.69m | 376.00 | 67.48 | 3.08 | 26.36 | 2.72 | 0.3911 | 0.3911 | 9.82 | 8.58 | 0.7897 | 2.10 | 7.05 | 367,561.20 | 3.15 | -1.85 | 3.49 | -2.18 | 79.38 | 82.93 | 3.99 | -2.98 | 3.97 | 5.84 | 0.1942 | -- | 32.65 | 10.27 | 94.37 | -- | -27.02 | -- |
| Pacific Biosciences of California Inc | 200.52m | -306.74m | 391.21m | 796.00 | -- | 0.5574 | -- | 1.95 | -1.21 | -1.21 | 0.7907 | 2.62 | 0.1142 | 2.70 | 7.24 | 251,910.80 | -17.46 | -16.19 | -19.45 | -17.81 | 28.03 | 37.35 | -152.97 | -136.21 | 7.21 | -22.45 | 0.5601 | -- | 56.29 | 20.59 | 2.39 | -- | 36.68 | -- |
| Neuropace Inc | 65.42m | -32.96m | 396.82m | 171.00 | -- | 18.86 | -- | 6.07 | -1.28 | -1.28 | 2.53 | 0.7423 | 0.590 | 1.65 | 6.61 | 382,578.90 | -29.72 | -- | -33.88 | -- | 73.56 | -- | -50.38 | -- | 5.02 | -4.97 | 0.7339 | -- | 43.72 | -- | 30.00 | -- | -- | -- |
| MaxCyte Inc | 41.29m | -37.92m | 405.05m | 143.00 | -- | 1.74 | -- | 9.81 | -0.3675 | -0.3675 | 0.3998 | 2.23 | 0.1488 | 0.4558 | 4.27 | 288,727.30 | -13.67 | -13.18 | -14.54 | -14.33 | 88.51 | 88.79 | -91.85 | -62.96 | 9.97 | -- | 0.00 | -- | -6.72 | 19.89 | -60.89 | -- | 39.13 | -- |
| Pulse Biosciences Inc | 0.00 | -42.21m | 406.46m | 56.00 | -- | 9.15 | -- | -- | -0.8936 | -0.8936 | 0.00 | 0.8044 | 0.00 | -- | -- | 0.00 | -61.61 | -93.21 | -67.89 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
| ZimVie Inc | 457.43m | -56.05m | 426.82m | 2.60k | -- | 1.04 | -- | 0.9331 | -2.12 | -14.87 | 17.33 | 15.12 | 0.3213 | 1.07 | 3.91 | 175,935.80 | -3.94 | -- | -4.56 | -- | 63.48 | 65.51 | -12.25 | -8.73 | 2.32 | -0.5562 | 0.5541 | -- | -1.26 | -16.08 | -19.50 | -- | -23.70 | -- |
| Nevro Corp | 425.17m | -92.21m | 451.91m | 1.22k | -- | 1.53 | -- | 1.06 | -2.57 | -2.57 | 11.82 | 8.06 | 0.6868 | 1.24 | 5.37 | 349,937.40 | -14.90 | -13.64 | -17.15 | -16.68 | 68.22 | 68.54 | -21.69 | -20.67 | 4.94 | -- | 0.4191 | -- | 4.63 | 1.88 | -3,172.74 | -- | 0.9012 | -- |
| Orthofix Medical Inc | 746.64m | -151.40m | 487.03m | 1.63k | -- | 0.8082 | -- | 0.6523 | -4.15 | -4.15 | 20.33 | 16.11 | 1.08 | 1.62 | 7.08 | 456,940.60 | -21.88 | -8.88 | -26.68 | -10.96 | 65.13 | 72.37 | -20.28 | -9.28 | 1.20 | -16.11 | 0.1595 | -- | 62.06 | 10.51 | -666.60 | -- | 30.01 | -- |
| Iradimed Corp | 65.56m | 17.19m | 511.07m | 148.00 | 29.88 | 7.15 | 28.46 | 7.80 | 1.35 | 1.35 | 5.15 | 5.64 | 0.738 | 1.69 | 5.14 | 442,988.50 | 19.35 | 13.16 | 22.51 | 14.58 | 76.50 | 76.55 | 26.22 | 21.46 | 3.87 | -- | 0.00 | 68.13 | 23.00 | 16.59 | 34.02 | 22.22 | 97.77 | -- |
| Nano-X Imaging Ltd | 9.91m | -60.78m | 524.05m | 180.00 | -- | 2.68 | -- | 52.91 | -1.08 | -1.08 | 0.1758 | 3.38 | 0.0419 | -- | 8.05 | -- | -25.72 | -30.98 | -28.14 | -35.10 | -66.55 | -- | -613.59 | -1,527.24 | 5.56 | -- | 0.0175 | -- | 15.47 | -- | 46.33 | -- | 114.35 | -- |
| Embecta Corp | 1.12bn | 55.30m | 595.94m | 2.20k | 10.78 | -- | 6.63 | 0.531 | 0.9598 | 0.9598 | 19.47 | -13.78 | 0.9296 | 2.57 | 19.35 | 510,181.80 | 4.58 | -- | 6.44 | -- | 66.55 | -- | 4.93 | -- | 1.75 | 1.67 | 1.94 | -- | -0.7703 | -- | -68.52 | -- | -- | -- |
| Fulgent Genetics Inc | 289.21m | -167.83m | 601.30m | 1.18k | -- | 0.5249 | -- | 2.08 | -5.64 | -5.64 | 9.71 | 38.31 | 0.2207 | -- | 5.57 | 244,267.70 | -13.37 | 16.70 | -14.25 | 18.37 | 36.12 | 67.89 | -60.59 | 29.06 | -- | -- | 0.0048 | 0.00 | -53.27 | 68.41 | -217.03 | -- | 57.08 | -- |
Data as of Apr 19 2024. Currency figures normalised to Nevro Corp's reporting currency: US Dollar USD
61.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 3.99m | 10.97% |
| Armistice Capital LLCas of 31 Dec 2023 | 3.18m | 8.73% |
| ArrowMark Colorado Holdings LLCas of 31 Dec 2023 | 3.01m | 8.27% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.84m | 7.81% |
| Engaged Capital LLCas of 20 Feb 2024 | 2.17m | 5.96% |
| Weatherbie Capital LLCas of 31 Dec 2023 | 2.06m | 5.66% |
| Braidwell LPas of 31 Dec 2023 | 1.78m | 4.88% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 1.20m | 3.31% |
| Rock Springs Capital Management LPas of 31 Dec 2023 | 1.03m | 2.82% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.02m | 2.79% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
